Purchase this article with an account.
M. E. Cavet, K. R. VanDerMeid, J. Zhang, K. W. Ward; Anti-Inflammatory Effects of Besifloxacin, a Novel Fluoroquinolone, in Primary Human Corneal Epithelial Cells. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2500.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The aim of this study was to determine the anti-inflammatory effects of besifloxacin, a novel fluoroquinolone under clinical evaluation for the treatment of ophthalmic infections, in human corneal epithelial cells.
Cytokine expression in primary human corneal epithelial cells (HCEpiC) was stimulated by IL-1ß and Luminex technology was used to determine the effect of besifloxacin on IL-1ß-induced cytokine expression. Moxifloxacin, a marketed fluoroquinolone, was used as the control. NFkB activation was assessed by measuring IΚB degradation and NFΚB nuclear translocation by Western blotting.
IL-1ß induced measurable cytokine expression for 12 of the 14 cytokines detected. Besifloxacin significantly inhibited IL-1ß-stimulated cytokine production in a dose-dependent manner, with a comparable (G-CSF, GM-CSF, IL-6, IL-8, MCP-1, and MIP-1ß) or better (TGF-α and TNF-α) potency compared to moxifloxacin. A significant inhibitory effect of besifloxacin was observed at 1 or 10 µg/mL. Besifloxacin inhibited both IΚB degradation and NFΚB nuclear translocation.
This PDF is available to Subscribers Only